Meeting
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
Authors
Edward Samuel James
Yale School of Medicine, New Haven, CT
Edward Samuel James , Gina Chung , Noelle Marie Sowers , Mary Beth Clark , Rebecca Lilian , Gineesha Abraham , Susan Chmael , Michelle Cappiello , Michael DiGiovanna , Erin Wysong Hofstatter , Tara Beth Sanft , Gary M. Israel , Lajos Pusztai , Lyndsay Harris , Maysa M. Abu-Khalaf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Survivorship and Health Policy,Systemic Therapy
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT00719875
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 154)
DOI
10.1200/jco.2013.31.26_suppl.154
Abstract #
154
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2015 ASCO Annual Meeting
Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
First Author: Haeseong Park
Poster
2014 ASCO Annual Meeting
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
First Author: Matthew R. Zibelman
Poster
2012 ASCO Annual Meeting
Phase I trial of ixabepilone and vorinostat in metastatic breast cancer.
First Author: Thehang H. Luu